AMLN
AMLN Articles
Amylin Pharmaceuticals (NASDAQ: AMLN) reported first quarter losses of $68.8 million, or $0.51 EPS, wider than the $49.4 million in the first quarter of 2007. Losses are credited to a drop in sales...
Published:
If you thought biotech news was getting quiet going into earnings season, think again. Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment for Parkinson’s...
Published:
Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers: Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to $28.97,...
Published:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is becoming a regular in this club. Yet another low of $28.02 intraday from a high of $53.25. It actually closed at $28.62, so it closed above the prior...
Published:
Last Updated:
There was a much larger list of companies which hit 52-week lows, but these were some of the larger percentage changes that we looked at: Amylin Pharmaceuticals Inc. (AMLN) closed at $29.34 versus a...
Published:
Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This data showed that Fampridine, which is designed to...
Published:
These are not the only impact analyst calls this morning, but these are the top calls that a673b.bigscoots-temp.com is focusing on: ABB Ltd. (NYSE: ABB) downgraded to SELL from Hold at Citigroup. Amylin Pharma...
Published:
Today has been a rough day with more 52-week lows than we can recall in quite some time. The biotechs haven’t been immune. You can even see that the Biotech HOLDRs (BBH) at $160+ are only about...
Published:
Last Updated:
Stock Tickers: AMGN, GILD, CELG, GENZ, MEDI, BIIB, AMLN, IMCL, DNDN, NFLD The short interest is on the rise overall, but the odd thing is that the short interest in biotech shares is really a mixed...
Published: